Clinigen Group Plc (CLIGF) Rating Lowered to Hold at Zacks Investment Research

Clinigen Group Plc (NASDAQ:CLIGF) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.

According to Zacks, “Clinigen Group plc is a pharmaceutical and services company. Its business focuses in areas of global medicine supply; clinical trial, unlicensed and licensed medicines. Clinigen Group plc is headquartered in Burton-on-Trent, the United Kingdom. “

Shares of Clinigen Group Plc (NASDAQ:CLIGF) opened at 13.90 on Friday. The stock has a market capitalization of $1.60 billion and a price-to-earnings ratio of 86.34. Clinigen Group Plc has a 52 week low of $8.70 and a 52 week high of $13.90.

WARNING: This piece was first reported by Sports Perspectives and is owned by of Sports Perspectives. If you are reading this piece on another domain, it was illegally copied and reposted in violation of United States and international copyright and trademark legislation. The correct version of this piece can be accessed at https://sportsperspectives.com/2017/09/10/clinigen-group-plc-cligf-rating-lowered-to-hold-at-zacks-investment-research.html.

Receive News & Ratings for Clinigen Group Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clinigen Group Plc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply